The Importance of Haematological and Biochemical Findings in Patients with West Nile Virus Neuroinvasive Disease

Open access

Summary

Background: West Nile virus neuroinvasive disease (WNND) occurs in less than 1% of infected people. Leukocytosis with lymphocytopenia, mild anaemia, thrombocytopenia, elevated liver and muscle enzymes and hyponatremia are occasionally present in patients with WNND. Cerebrospinal fluid (CSF) findings resemble other viral neuroinfections. The purpose of this study is to present some of the most important laboratory findings of our patients with WNND and to evaluate their correlation with fatal outcome.

Methods: The study included 161 patients with WNND. Their blood and CSF samples were cytobiochemically analysed and the obtained variables were then tested for predictive significance of the disease outcome, or used for differentiation between two clinical syndromes (encephalitis vs meningitis).

Results: West Nile encephalitis was present in 127 (78.9%) patients and West Nile meningitis was diagnosed in 34 (21.1%) cases. Leukocytosis was found in 45.9% patients. CRP level higher than 100 mg/L was registered only in those with encephalitis (p=0.020). CSF leukocyte count was 146±171 per microlitre, with slight lymphocytic predominance (mean 52%). Hypoglycorrhachia was registered in 9.3% of our patients with WNND. Twenty-eight (17.4%) patients died and all of them had encephalitis. Independent predictors of fatal outcome in WNND were serum CRP > 100 mg/L (p=0.011) and CSF proteins > 1 g/L (p=0.002).

Conclusions: WNND usually affects older males. Prolonged neutrophilic predominance in CSF can occasionally be present, as well as hypoglycorrhachia. Patients with encephalitis, high serum CRP and high CSF protein level have a higher risk of fatal outcome.

1. Popović N, Milošević B, Urošević A, Poluga J, Lavadinović L, Nedeljković J, et al. Outbreak of West Nile virus infection among humans in Serbia, August to October 2012. Eurosurveillance 2013; 18: 20613.

2. Davis LE, DeBiasi R, Goade DE, Haaland KY, Harrington JA, Harnar JB, et al. West Nile virus neuroinvasive disease. Annals of Neurology 2006; 60: 286–300.

3. Lima-Oliveira G, Lippi G, Luca Salvagno G, Picheth G, Guidi CG. Laboratory diagnostics and quality of blood collection. J Med Biochem 2015; 34: 288–294.

4. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis 2002; 2: 519–29.

5. European Center for Disease Prevention and Control (ECDC). EU case definition. Stockholm: ECDC. [Accessed 28 Mar 2016]. Available from: http://ecdc.europa.eu/en/healthtopics/west_nile_fever/EU-case-definition/Pages/EU-case-definition.aspx.

6. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–4.

7. Nash D, Mostashari F, Fine A, Miller J, O’Leary D, Murray K, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001; 344: 1807–14.

8. Chowers MY, Lang R, Nassar F, Ben-David D, Giladi M, Rubinshtein E, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001; 7: 675–8.

9. Weiss D, Carr D, Kellachan J, Tan C, Phillips M, Bresnitz E, et al. Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg Infect Dis 2001; 7: 654–8.

10. Sejvar JJ, Haddad MB, Tierney BC, Campbell GL, Marfin AA, Van Gerpen JA, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003; 290: 511–5.

11. Burton JM, Kern RZ, Halliday W, Mikulis D, Brunton J, Fearon M, et al. Neurological manifestations of West Nile virus infection. Can J Neurol Sci 2004; 31: 185–93.

12. Georges AJ, Lesbordes JL, Georges-Courbot MC, Meunier DMY, Gonzalez JP. Fatal hepatitis from West Nile virus. Ann l’Institut Pasteur/Virol 1987; 138: 237–44.

13. Jeha LE, Sila CA, Lederman RJ, Prayson RA, Isada CM, Gordon SM. West Nile virus infection: a new acute paralytic illness. Neurology 2003; 61: 55–9.

14. Medarov BI, Multz AS, Brown W, Lempert L. West Nile meningoencephalitis and rhabdomyolysis. Lancet Infect Dis 2005; 5: 2.

15. Tyler KL, Pape J, Goody RJ, Corkill M, Kleinschmidt-DeMasters BK. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology 2006; 66: 361–5.

16. Jaijakul S, Arias CA, Hossain M, Arduino RC, Wootton SH, Hasbun R. Toscana meningoencephalitis: A comparison to other viral central nervous system infections. J Clin Virol 2012; 55: 204–8.

17. Varki AP, Puthuran P. Value of second lumbar puncture in confirming a diagnosis of aseptic meningitis. A prospective study. Arch Neurol 1979; 36: 581–2.

18. Bai F, Kong K, Dai J, Qian F, Zhang L, Brown CR, et al. A Paradoxical Role for Neutrophils in the Pathogenesis of West Nile Virus. J Infect Dis 2010; 202: 1804–12.

19. Pepperell C, Rau N, Krajden S, Kern R, Humar A, Mederski B, et al. West Nile virus infection in 2002: morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ 2003; 168: 1399–405.

20. Crichlow R, Bailey J, Gardner C. Cerebrospinal fluid neutrophilic pleocytosis in hospitalized West Nile virus patients. J Am Board Fam Pract 2004; 17: 470–2.

21. Rawal A, Gavin PJ, Sturgis CD. Cerebrospinal fluid cytology in seasonal epidemic West Nile virus meningoencephalitis. Diagn Cytopathol 2006; 34: 127–9.

22. Chow E, Troy SB. The Differential Diagnosis of Hypoglycorrhachia in Adult Patients. Am J Med Sci 2014; 348: 186–90.

23. Cunha BA. The diagnostic usefulness of cerebrospinal fluid lactic acid levels in central nervous system infections. Clin Infect Dis 2004; 39: 1260–1.

24. Đorđević D, Pejović J, Surbatović M, Jevđić J, Radaković S, Veljović M, Perić A, Anđelić T, Popović N. Prognostic value and daily trend of interleukin-6, neutrophil cd64 expression, c-reactive protein and lipopolysaccharide-binding protein in critically ill patients: reliable predictors of outcome or not? J Med Biochem 2015; 34: 431–9.

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

Journal Information


IMPACT FACTOR 2018: 2,000
5-year IMPACT FACTOR: 1,075



CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 246 190 36
PDF Downloads 88 78 7